Bristol Myers Squibb CO 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
Bristol Myers Squibb reported a 6% increase in Q2 2026 revenue to $12.97 billion and a significant rise in diluted EPS to $1.62, driven by strong performance in its Growth Portfolio and Eliquis.
NYSE
Bristol Myers Squibb reported a 3% increase in total revenues for the first quarter of 2026, driven by its Growth Portfolio and Eliquis, despite generic erosion in its Legacy Portfolio.
NYSE
Bristol-Myers Squibb reported a significant increase in Q3 net earnings and diluted EPS, driven by strong performance in its Growth Portfolio and strategic business development activities, despite ongoing generic erosion of legacy products.
NYSE
Bristol-Myers Squibb reported a 1% increase in total revenues for Q2 2025, driven by growth in its new portfolio, but saw a decline in GAAP and non-GAAP EPS due to significant R&D investments and ongoing generic erosion of legacy products.
NYSE
10-Q: Bristol-Myers Squibb Reports Q1 2025 Earnings, Revenue Declines Amid Growth Portfolio Expansion
Bristol-Myers Squibb's Q1 2025 results show a revenue decrease of 6% despite growth in key products, impacted by generic erosion and changes in the U.S. Medicare Part D program.
NYSE
Bristol-Myers Squibb's Q3 2024 results show revenue growth driven by key products, but are impacted by significant acquisition costs and restructuring charges.
NYSE
Bristol-Myers Squibb's second-quarter results show revenue growth driven by key products, but are impacted by significant acquisition costs and restructuring charges.
NYSE
Bristol-Myers Squibb's first quarter 2024 results were significantly impacted by acquisition-related expenses, leading to a net loss despite a revenue increase.